Identification of a novel fluoropyrrole derivative as a potassium-competitive acid blocker with long duration of action

Bioorganic and Medicinal Chemistry

Volumn 25, Issue 13, 2017, Pages 3298-3314

  Nishida, Haruyuki ^a   Arikawa, Yasuyoshi ^a   Hirase, Keizo ^a   Imaeda, Toshihiro ^a   Inatomi, Nobuhiro ^a   Hori, Yasunobu ^a   Matsukawa, Jun ^a   Fujioka, Yasushi ^a   Hamada, Teruki ^a   Iida, Motoo ^a   Nishitani, Mitsuyoshi ^a   Imanishi, Akio ^a   Fukui, Hideo ^a   Itoh, Fumio ^a   Kajino, Masahiro ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Fluoropyrrole; H+,K+ ATPase; Long duration of action; Low lipophilicity; Potassium competitive acid blocker

Indexed keywords

1 [1 [(3 FLUOROPHENYL)SULFONYL] 5 (2 FLUOROPYRIDIN 3 YL) 1H PYRROL 3 YL] N METHYLMETHANAMINE HYDROCHLORIDE; 1 [5 (2 CHLOROPYRIDIN 3 YL) 1 (PHENYLSULFONYL) 1H PYRROL 3 YL] N METHYLMETHANAMINE HYDROCHLORIDE; 1 [5 (2 CHLOROPYRIDIN 3 YL) 1 (PYRIDIN 3 YLSULFONYL) 1H PYRROL 3 YL] N METHYLMETHANAMINE FUMARATE; 1 [5 (2 FLUOROPHENYL) 1 [(4 METHYLPHENYL)SULFONYL] 1H PYRROL 3 YL] N METHYLMETHANAMINE HYDROCHLORIDE; 1 [5 (2 FLUOROPYRIDIN 3 YL) 1 (FURAN 2 YLSULFONYL) 1H PYRROL 3 YL] N METHYLMETHANAMINE FUMARATE; 1 [5 (2 FLUOROPYRIDIN 3 YL) 1 (FURAN 3 YLSULFONYL) 1H PYRROL 3 YL] N METHYLMETHANAMINE HYDROCHLORIDE; 1 [5 (2 FLUOROPYRIDIN 3 YL) 1 (PHENYLSULFONYL) 1H PYRROL 3 YL] N METHYLMETHANAMINE FUMARATE; 1 [5 (2 FLUOROPYRIDIN 3 YL) 1 (PYRIDIN 2 YLSULFONYL) 1H PYRROL 3 YL] N METHYLMETHANAMINE HYDROCHLORIDE; 1 [5 (2 FLUOROPYRIDIN 3 YL) 1 (PYRIDIN 3 YLSULFONYL) 1H PYRROL 3 YL] N METHYLMETHANAMINE FUMARATE; 1 [5 (2 FLUOROPYRIDIN 3 YL) 1 (THIOPHEN 2 YLSULFONYL) 1H PYRROL 3 YL] N METHYLMETHANAMINE FUMARATE; 1 [5 (2 FLUOROPYRIDIN 3 YL) 1 (THIOPHEN 3 YLSULFONYL) 1H PYRROL 3 YL] N METHYLMETHANAMINE FUMARATE; 1 [5 (2 FLUOROPYRIDIN 3 YL) 1 [(3 METHOXYPHENYL)SULFONYL] 1H PYRROL 3 YL] N METHYLMETHANAMINE FUMARATE; 1 [5 (2 FLUOROPYRIDIN 3 YL) 1 [(6 METHOXYPYRIDIN 3 YL)SULFONYL] 1H PYRROL 3 YL] N METHYLMETHANAMINE HYDROCHLORIDE; 1 [5 (3 FLUOROPHENYL) 1 [(4 METHYLPHENYL)SULFONYL] 1H PYRROL 3 YL] N METHYLMETHANAMINE HYDROCHLORIDE; 1 [5 (4 FLUOROPHENYL) 1 [(4 METHYLPHENYL)SULFONYL] 1H PYRROL 3 YL] N METHYLMETHANAMINE HYDROCHLORIDE; 3 [4 [(METHYLAMINO)METHYL] 1 (PHENYLSULFONYL) 1H PYRROL 2 YL]PYRIDINE 2 CARBONITRILE HYDROCHLORIDE; 3 [4 [(METHYLAMINO)METHYL] 1 (PYRIDIN 3 YLSULFONYL) 1H PYRROL 2 YL]PYRIDINE 2 CARBONITRILE FUMARATE; 3 [[2 (2 FLUOROPYRIDIN 3 YL) 4 [(METHYLAMINO)METHYL] 1H PYRROL 1 YL]SULFONYL]BENZONITRILE FUMARATE; ADENOSINE TRIPHOSPHATASE; N METHYL 1 [1 (PHENYLSULFONYL) 5 (PYRIDIN 2 YL) 1H PYRROL 3 YL]METHANAMINE OXALATE; N METHYL 1 [1 (PHENYLSULFONYL) 5 (PYRIDIN 3 YL) 1H PYRROL 3 YL]METHANAMINE DIHYDROCHLORIDE; N METHYL 1 [1 (PHENYLSULFONYL) 5 (PYRIMIDIN 5 YL) 1H PYRROL 3 YL]METHANAMINE HYDROCHLORIDE; N METHYL 1 [1 [(4 METHYLPHENYL)SULFONYL] 5 [2 (TRIFLUOROMETHYL)PHENYL] 1H PYRROL 3 YL]METHANAMINE HYDROCHLORIDE; N METHYL 1 [5 (2 METHYLPHENYL) 1 [(4 METHYLPHENYL)SULFONYL] 1H PYRROL 3 YL]METHANAMINE HYDROCHLORIDE; N METHYL 1 [5 (2 METHYLPYRIDIN 3 YL) 1 (PYRIDIN 3 YLSULFONYL) 1H PYRROL 3 YL]METHANAMINE FUMARATE; POTASSIUM COMPETITIVE ACID BLOCKER; POTASSIUM ION; PROTON; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; POTASSIUM CHANNEL HERG; PROTON PUMP INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; GASTRIC HYPERACIDITY; IC50; LIPOPHILICITY; NONHUMAN; PH; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOG; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; HEP-G2 CELL LINE; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; STOMACH ACID; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; CELL SURVIVAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHER-A-GO-GO POTASSIUM CHANNELS; GASTRIC ACID; H(+)-K(+)-EXCHANGING ATPASE; HEK293 CELLS; HEP G2 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MOLECULAR STRUCTURE; PROTON PUMP INHIBITORS; PYRROLES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85018752175     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2017.04.014     Document Type: Article

References (33)

1. 1 Sachs, G., Carlsson, E., Lindberg, P., Wallmark, B., Gastric, H., K-ATPase as therapeutic target. Ann Rev Pharmacal Toxical 28 (1988), 269–284.
2. 2 Nagaya, H., Satoh, H., Kubo, K., Maki, Y., Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther 248 (1989), 799–805.
3. 3 Wolfe, M.M., Sachs, G., Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 118 (2000), S9–S31.
4. 4 Shin, J.M., Cho, Y.M., Sachs, G., Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc 126 (2004), 7800–7811.
5. 5 Shi, S., Klotz, U., Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 64 (2008), 935–951.
6. 6 Graham, D.Y., Agrawal, N.M., Campbell, D.R., et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162 (2002), 169–175.
7. 7 Frazzoni, M., De Micheli, E., Grisendi, A., Savarino, V., Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. Aliment Pharmacol Ther 17 (2003), 235–241.
8. 8 Robinson, M., Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract 59 (2005), 709–715.
9. 9 Malfertheiner, P., Mössner, J., Fischbach, W., et al. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther 18 (2003), 615–625.
10. 10 Fass, R., Shapiro, M., Dekel, R., Sewell, J., Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease–where next?. Aliment Pharmacol Ther 22 (2005), 79–94.
11. 11 Dammann, H.G., Burkhardt, F., Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol 11 (1999), 1277–1282.
12. 12 Katz, P.O., Hatlebakk, J.G., Castell, D.O., Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 14 (2000), 709–714.
13. 13 Ang, T.L., Fock, K.M., Nocturnal acid breakthrough: clinical significance and management. J Gastroenterol Hepatol 21 (2006), S125–S128.
14. 14 Furuta, T., Shirai, N., Sugimoto, M., Nakamura, A., Hishida, A., Ishizaki, T., Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20 (2005), 153–167.
15. 15 Andersson, K., Carlsson, E., Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 108 (2005), 294–307.
16. 16 Yoon, Y.A., Park, C.S., Cha, M.H., Choi, H., Sim, J.Y., Kim, J.G., Novel pyrimidines as acid pump antagonists (APAs). Bioorg Med Chem Lett 20 (2010), 5735–5738.
17. 17 Inatomi, N., Matsukawa, J., Sakurai, Y., Otake, K., Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharmacol Ther 168 (2016), 12–22.
18. 18 Garnock-Jones, K.P., Vonoprazan: first global approval. Drugs 75 (2015), 439–443.
19. 19 Kaminski, J.J., Bristol, J.A., Puchalski, C., et al. Antiulecer agents. 1. Gastric antisecretory and cytoprotective properties of substituted imidazo[1,2-a]pyridines. J Med Chem 28 (1985), 876–892.
20. 20 Gedda, K., Briving, C., Svensson, K., Maxvall, I., Andersson, K., Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+, K+-ATPase. Biochem Pharmacol 73 (2007), 198–205.
21. 21 Kahrilas, P.J., Dent, J., Lauritsen, K., et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 5 (2007), 1385–1391.
22. 22 Ito, K., Kinoshita, K., Tomizawa, A., et al. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526). J Pharmacol Exp Ther 323 (2007), 308–317.
23. 23 Simon, W.A., Herrmann, M., Klein, T., et al. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther 321 (2007), 866–874.
24. 24 Parsons, M.E., Keeling, D.J., Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs 14 (2005), 411–421.
25. 25 Nishida, H., Hasuoka, A., Arikawa, Y., et al. Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers. Bioorg Med Chem 20 (2012), 3925–3938.
26. 26 Hori, Y., Imanishi, A., Matsukawa, J., et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 335 (2010), 231–238.
27. 27 Hori, Y., Matsukawa, J., Takeuchi, T., Nishida, H., Kajino, M., Inatomi, N., A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 337 (2011), 797–804.
28. 28 Arikawa, Y., Nishida, H., Kurasawa, O., et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1- (pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P- CAB). J Med Chem 55 (2012), 4446–4456.
29. 29 Leeson, P.D., Springthorpe, B., The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6 (2007), 881–890.
30. 30 Yamamoto, K., Ikeda, Y., Kinetic solubility and lipophilicity evaluation connecting formulation technology strategy perspective. J Drug Deliv Sci Technol 33 (2016), 13–18.
31. 31 Böhm, H.J., Banner, D., Bendels, S., et al. Fluorine in medicinal chemistry. ChemBioChem 5 (2004), 637–643.
32. 32 Imai, Y.N., Ryu, S., Oiki, S., Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach. J Med Chem 52 (2009), 1630–1638.
33. 33 Sheldrick, G.M., A short history of SHELX. Acta Crystallogr A 64 (2008), 112–122.